Suchergebnisse - "Gregersen, Henrik"

PubPharm (91)

1

Socioeconomic Status and Overall Survival Among Patients With Hematological Malignant Neoplasms

enthalten in: JAMA network open | 2024

von Nielsen, L. | Kristensen, D. | Jakobsen, L. | +5

2

Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma : a randomized phase 2 trial by the Nordic Myeloma Study Group

enthalten in: Journal of patient-reported outcomes | 2024

von Nielsen, L. | Schjesvold, F. | Möller, S. | +7

3

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

CommentIn: N Engl J Med. 2024 Apr 18;390(15):1440. - PMID 38631009

4

Geographical and ecological analyses of multiple myeloma in Denmark : Identification of potential hotspot areas and impact of urbanisation

enthalten in: European journal of haematology | 2023

von Bertelsen, L. | Børty Nielsen, L. | Christensen, H. | +10

5

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

enthalten in: BMC cancer | 2022

von Schmitz, A. | Brøndum, R. | Johnsen, H. | +24

6

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

enthalten in: BMC cancer | 2022

von Schmitz, A. | Brøndum, R. | Johnsen, H. | +24

7

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

enthalten in: BMC cancer | 2022

von Schmitz, A. | Brøndum, R. | Johnsen, H. | +24

8

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group

enthalten in: European journal of haematology | 2022

von Gregersen, H. | Peceliunas, V. | Remes, K. | +18

9

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group

enthalten in: European Journal of Haematology | 2022

von Gregersen, H. | Peceliunas, V. | Remes, K. | +18

10

Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries

enthalten in: European Journal of Haematology | 2022

von Blimark, C. | Vangsted, A. | Klausen, T. | +7

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]